Gerson James N, Skariah Sam, Denlinger Crystal S, Astsaturov Igor
a Department of Hemagology/Oncology , Fox Chase Cancer Center , Philadelphia , PA , USA.
b Abington Memorial Hospital , Abington , PA , USA.
Expert Opin Investig Drugs. 2017 May;26(5):531-540. doi: 10.1080/13543784.2017.1315406.
The blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers. Areas covered: Here, we review complex HER2 biology, current methods of HER2 testing and tumor heterogeneity of gastroesophageal cancer. Ongoing and completed clinical research data are discussed. Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting. With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy. Clonal heterogeneity and emergence of resistance will challenge our approach to treating these patients beyond the frontline settings.
HER2信号通路的阻断显著改善了食管胃癌患者的预后。然而，由于该受体在胃癌和食管癌中的生物学特性复杂，靶向HER2仍然具有挑战性。涵盖领域：在此，我们综述了HER2复杂的生物学特性、目前HER2检测方法以及胃食管癌的肿瘤异质性。讨论了正在进行和已完成的临床研究数据。专家观点：HER2过表达是胃食管癌中一个经过验证的靶点，在一线治疗中抑制HER2可延长生存期，具有治疗意义。随着胃食管癌中HER2检测的标准化，正在进行的试验正在测试更新的药物和联合方案，包括抗HER2抗体与免疫疗法的联合。克隆异质性和耐药性的出现将挑战我们在一线治疗之外治疗这些患者的方法。
